CA 19-9 tumour marker: when it is tested and how results are interpreted

CA 19-9 is a tumour marker measured in blood, used mainly in pancreatic and bile duct cancer to monitor already diagnosed disease and assess response to treatment. It is not a test for detecting cancer in people without symptoms, because it may also be elevated in benign conditions and remains normal in some people with cancer.

Who is this test for

• people with confirmed pancreatic or bile duct cancer, before treatment begins,
• people being treated for pancreatic or bile duct cancer, to assess treatment response,
• people attending follow-up after surgery to check for possible recurrence,
• people whose symptoms or ultrasound findings already lead the doctor to suspect a pancreatic or bile duct tumour, alongside bilirubin and liver enzymes.

What CA 19-9 is

CA 19-9 (carbohydrate antigen 19-9) is a sugar structure on cell surfaces, chemically the sialyl-Lewis a antigen. Healthy pancreatic, bile duct and digestive tract cells also produce small amounts, while many pancreatic and bile duct tumours produce much larger amounts.

Its production requires an enzyme associated with Lewis blood groups. Some people, most often Lewis-negative (Lewis a−b−), produce very little CA 19-9 or levels cannot be measured at all. Estimates suggest that a few percent to around 10 % of people are Lewis-negative. In these people the marker may remain low even with a tumour, and its usefulness for monitoring also depends on its baseline value.

In confirmed pancreatic or bile duct cancer, CA 19-9 is measured before and during treatment. A fall usually means the disease is responding to treatment, while a rise may indicate progression. If CA 19-9 fell after surgery, a renewed rise may be the first sign of recurrence. Such findings are always checked with imaging. When a tumour is suspected, however, diagnosis is established through CT, MRI, endoscopic ultrasound and tissue sample analysis.

In jaundice, it makes sense to measure the baseline only after bile drainage is restored, because bile stasis itself raises CA 19-9.

Why CA 19-9 is not an early cancer detection test

CA 19-9 is often normal in small early-stage tumours, may remain low despite a tumour in some people, particularly those who are Lewis-negative, and is elevated in many benign conditions. Professional guidelines, including those of the American Society of Clinical Oncology (ASCO), therefore do not recommend it for screening healthy people. A normal result does not rule out cancer, and an elevated result does not prove it.

If you have jaundice, unexplained weight loss or upper abdominal pain radiating to the back, see your doctor. Read more in the article on early signs of pancreatic cancer.

When CA 19-9 is elevated

Benign conditions

• bile stasis (bile duct obstruction) due to a stone or bile duct narrowing – one of the most common causes of elevation without cancer,
• inflammation of the bile ducts (cholangitis) and gallbladder,
• acute and chronic pancreatic inflammation (pancreatitis),
• liver diseases such as cirrhosis and chronic hepatitis.

In bile stasis and cholangitis, the value may exceed 1000 kIU/L and generally falls once bile drainage is restored.

Malignant diseases

• pancreatic cancer, in which higher values usually accompany more advanced disease,
• bile duct cancer (cholangiocarcinoma) and gallbladder cancer,
• less commonly stomach, colorectal and liver cancer, and certain ovarian tumours.

CA 19-9 is not specific for tumours outside the pancreas and bile ducts. In colorectal cancer the doctor more often relies on CEA, and in ovarian cancer on CA 125.

Save with a panel

Test CA 19-9 is also included in this panel.

Tumour marker panel – womenCEA, CA 19-9, CA125, CA 15-3Price of individual tests: 79.00€71.00€Details ›

Preparation and sample

CA 19-9 is measured in a venous blood sample. Fasting is not essential unless tests requiring it, such as glucose, are performed at the same time. If you take biotin (for example, hair and nail supplements), mention this when your blood is drawn.

Normal values and interpretation of results

Results are expressed in kIU/L, numerically equivalent to U/mL. In most laboratories the upper reference limit is 37 kIU/L, but this depends on the method, so use the interval printed on your report.

• For monitoring, the trend matters more than an individual number. The doctor compares results with the baseline. If CA 19-9 was not elevated even before treatment, monitoring relies on imaging.
• Have follow-up tests in the same laboratory. Results obtained using different methods are not directly comparable.

A slightly elevated value is assessed alongside bilirubin, liver enzymes, lipase and imaging, because one result is not a diagnosis.

How to arrange testing

You can come for blood collection without an appointment or referral at one of our branches throughout Croatia (listed on the Contact). Prices for all tests and panels are on the service price list.

CA 19-9 is also included in two tumour marker panels: Marker panel – women (CEA, CA 19-9, CA 125, CA 15-3) and Marker panel – men (CEA, CA 19-9, PSA, AFP). In someone without symptoms, measuring more markers does not replace preventive examinations and increases the likelihood of a false-positive result. Read what each marker shows in the overview of tumour markers.

Frequently asked questions

What does CA 19-9 above 1000 or above 10 000 mean?

Such high values occur more often in malignancy, particularly advanced pancreatic or bile duct cancer, but also in severe bile stasis or cholangitis. Even a very high number is not a diagnosis by itself.

Can CA 19-9 be normal despite pancreatic cancer?

Yes, particularly in small tumours and Lewis-negative people. If symptoms or suspicious imaging findings are present, normal CA 19-9 does not rule out cancer.

Should CA 19-9 be tested preventively?

No. CA 19-9 has no proven benefit in people without symptoms, and a false-positive result leads to unnecessary investigations. Prevention is supported by national early detection programmes for breast, colorectal, cervical and lung cancer if you are in an eligible group.